Optimi Health Launches Standardized 1mg and 2mg Microdose Psilocybin Products for Clinical Research
OPTH sits 45% above its 52-week low of $3.
Summary
Optimi Health Corp. announced the production of new 1mg and 2mg standardized microdose psilocybin products, targeting clinical research organizations with consistent, validated doses.
Key Events · Product Development and Regulatory · OPTH
-
New Microdose Psilocybin Products
Optimi Health has completed production of 1mg and 2mg standardized microdose psilocybin finished drug products.
-
Targeting Clinical Research
These products are specifically designed for qualified clinical research organizations, providing consistent, validated doses of naturally derived psilocybin.
-
Expanded Product Range
This expands Optimi's psilocybin portfolio, which already includes a 5mg capsule formulation commercially prescribed in Australia.
-
In-House GMP Production
All products are cultivated, extracted, formulated, and packaged in-house at Optimi's GMP-compliant facility in British Columbia, Canada.
Analysis · OPTH · Life Sciences
Optimi Health has launched new standardized microdose psilocybin products (1mg and 2mg) specifically for clinical research. This is important because it addresses a critical need in psychedelic research for consistent, validated doses, which is often a challenge with naturally derived products. Expanding their product line for research organizations could open new revenue streams and solidify their position as a key supplier in the emerging psychedelic medicine market.
At the time of this filing, OPTH was trading at $4.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.1M. The 52-week trading range was $3.00 to $8.84. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.